Cerebain Biotech Applauds Congressional Passage of 21st Century Cures Act

COSTA MESA, Calif.--()--Cerebain Biotech (OTCQB: CBBT) today applauded the Congressional passage of the 21st Century Cures Act. The law has the potential to invigorate medical research, promote innovation and speed the development of new treatments for Alzheimer’s and other chronic diseases.

The Cures Act is designed to reduce the regulatory burden on drug and medical device discovery and development, to increase the speed of reviewing those products that have been researched through the FDA, and to get them into patients' hands more quickly.

Eric Clemons, President of Cerebain, stated, “Supporters of the Cures Act hope the law will mean research facilities may not need to pay as much for expenses needed for research and development of drugs. The legislation now allows drug makers to use real world experience, reducing reliance on clinical trials to acquire acceptable data.” Mr. Clemons went on to say, “We encourage you to connect with us on Twitter and Facebook to stay informed.”

About Cerebain Biotech Corp.

Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.

Forward Looking Statements

This news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Contacts

Cerebain Biotech Corp.
Mr. Alan Klitenic, 888-430-2221
info@cerebain.com

Contacts

Cerebain Biotech Corp.
Mr. Alan Klitenic, 888-430-2221
info@cerebain.com